Aggressive Disease Treatment Patterns and CtDNA HRR evaluatiON in High-volume metastatiC hORmone-sensitive Prostate Cancer in Russian FeDeration
About this study
A multicentre observational study on treatment patterns and ctDNA HRR evaluation in aggressive high-volume metastatic hormone-sensitive prostate cancer in Russian Federation
- Condition
- Prostate Cancer
- Sponsor
- AstraZeneca
Who can join
- Age
- 18 years and older
- Sex
- Male only
- Healthy volunteers
- Not accepted
Inclusion 10
- Minimum age: 18 years
- Eligible sex: Male
- Study condition: Prostate Cancer
- Male patients aged ≥ 18 years old;
- Signed ICF, including consent for blood samples ctDNA and ctDNA-based HRRm testing;
- Metastatic hormone-sensitive prostate cancer (mHSPC) (de novo or progressed from earlier stages);
- High-aggressive disease (Gleason 8-10);
- High-volume disease (according to CHAARTED trial criteria: presence of 4 and more (≥4) bone metastases (including at least one (≥1) outside the vertebral column/pelvis) and/or 1 and more (≥1) visceral metastasis);
- Availability of source medical documentation;
- Known HRRm status based on tumour sample evaluation performed in routine practice.
Exclusion 2
- Participation in any interventional trial since the mPC diagnosis.
- Progression to mCRPC.
Where
26 sites, 20 recruiting
Research Site
Arkhangelsk, Russia
Research Site
Barnaul, Russia
Research Site
Chelyabinsk, Russia
Research Site
Irkutsk, Russia
Research Site
Krasnodar, Russia
Research Site
Krasnoyarsk, Russia
and 20 more sites on ClinicalTrials.gov
Contact
-
AstraZeneca Clinical Study Information Center
1-877-240-9479 information.center@astrazeneca.com
Potential match only. Final eligibility is determined by the study team.